NCT04216524View on ClinicalTrials.gov

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IT or IV

DRUG

Dexamethasone

Given PO or IV

DRUG

Doxorubicin

Given IV

DRUG

Mercaptopurine

Given PO

DRUG

Methotrexate

Given IT, IV, or PO

DRUG

Methylprednisolone

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Tagraxofusp-erzs

Given IV

DRUG

Venetoclax

Given PO

DRUG

Vincristine

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER